All In Biotech

Free tool

FAERS Monitor: Saphnelo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761451 or its brand name (Saphnelo, Anifrolumab-Fnia). Reports on generic versions are filed under their own applications.

Reports

1,921

Serious

1,057

55% of reports

Hospitalization

332

Death reported

81

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • systemic lupus erythematosus168
  • fatigue147
  • arthralgia109
  • headache98
  • nausea88
  • pain79
  • rash78
  • herpes zoster69
  • drug ineffective67
  • product dose omission issue62
  • condition aggravated59
  • dyspnoea55
  • dizziness52
  • covid-1951
  • pruritus51

Reports by year received

View as table
YearReports
202123
2022191
2023383
2024478
2025465
2026381

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,238 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
systemic lupus erythematosusSignal16852.145.08,338
herpes zosterSignal6913.210.4765
covid-19Signal513.22.475
arthralgiaSignal1092.92.4134
product dose omission issueSignal622.31.845
condition aggravatedSignal592.11.735
fatigueSignal1472.11.883
rash782.01.636
headache981.71.429
pruritus511.51.17
pain791.41.19
nausea881.21.03
dizziness521.10.91
dyspnoea551.10.80
drug ineffective670.60.425

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.